Who
Atabak Mokari
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Corcept Therapeutics; Chief Financial Officer, Bellicum Pharmaceuticals; CFO and VP Corp Development, Iridex.
In numbers
- Trades disclosed
- 133
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $37.5M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 27 Jul 2016
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $12K102 at $113.38 | filing |
| 2 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $12K102 at $113.38 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $16K138 at $113.38 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —138 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $16K138 at $113.38 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —138 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $1.8M80,000 at $23.06 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $829K7,089 at $116.96 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $975K8,267 at $117.93 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $568K4,783 at $118.73 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $972K8,103 at $119.95 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $121K1,001 at $120.67 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $443K4,200 at $105.54 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $958K8,956 at $106.96 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $43K400 at $108.46 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $242K2,202 at $110.03 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $67K600 at $110.95 | filing |
| 30 Jul 2026filed 3 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $532K4,700 at $113.18 | filing |
News
No headline names them, or the companies they trade most, lately.